Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

NCT04594798 is registered in ClinicalTrials.gov with University of Rochester as lead sponsor.

NCT NCT04594798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04594798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
Lead sponsor
University of Rochester
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 20, 2021
Completion date
July 31, 2027
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dlbcl, lymphoma, b-cell